Loading…
← CockpitCompetitor Analysis › SGP SpyGlass Pharma, Inc.Open in the cockpit ↗

SpyGlass Pharma, Inc.SGPCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum leader 90
Mkt cap
$993M
US dollars, full cap
Free float
42%
of shares outstanding
$/day
$4.10M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.6%
Hurdle
n/a
no reverse DCF
Next earnings
128 days
26 Mar 2027
Close · USD$29.68
1D-5.6%
1W-15.1%
1M+13.5%
3M+13.2%
6M+35.6%
YTDn/a
1Yn/a
ATR %7.9%
52w lowhigh25.6% off high

What SpyGlass Pharma does

Employees: 65

SpyGlass Pharma at a glance

Size SpyGlass Pharma (SGP) is a United States Health Care company (Biotechnology) with a market value of $993M, the 2238th largest of 3,085 United States companies the cockpit tracks. Shares closed at $29.68 on 18 Nov 2026.

Performance Over six months the shares gained 35.6%, against -15.1% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 20 in its peer set.

Short interest Short interest is 3.5% of the free float (30 Oct 2026).

Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026SGP 135Peer median 85
Six months, rebased to 100: SpyGlass Pharma against the median of its 20 peers (local-currency closes).

SpyGlass Pharma financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023
Revenue$0$0$0$0
Revenue growth————
Gross profit-$1.16M-$612,000-$271,418-$122,668
EBITDA-$76.1M-$40.8M-$26.8M-$14.1M
Net income-$70.5M-$39.9M-$29.2M-$13.3M
Free cash flown/a-$33.5M-$24.0M-$12.5M
Capital expendituren/a$789,000$1.99M$216,542
Total debt$1.61M$1.58M$3.90M$0

Quarterly statements and history in the cockpit →

SpyGlass Pharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%688276INBXANRO3004820020309606600195JBIO688253ODTX2160VOR4587VSTMCMPSAKUMSMGTXSGP6-month return →1-month return →
Up and to the right = strong over both horizons. SpyGlass Pharma is the large dot.

SpyGlass Pharma competitors and peer comparison

How SpyGlass Pharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

SpyGlass Pharma against its 20 peers (data as of 18 Nov 2026)
MeasureSGPPeer medianRank in peer set
1-month return+13.5%-8.8%highest of 21
6-month return+35.6%-15.1%3rd highest of 20
Distance from 52-week high-25.6%-40.8%2nd highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
SpyGlass Pharma SGPUnited States$993M+36%n/an/an/an/an/a
Changchun BCHT Biotechnology 688276.SSChina$992M-2%+2%-29%9.9×n/an/a
Inhibrx Biosciences INBXUnited States$1.02B-37%+43%-6,287%551.0×n/an/a
Alto Neuroscience ANROUnited States$1.04B+25%n/an/an/an/an/a
Guangzhou Wondfo Biotech 300482.SZChina$1.05B-18%-24%-2%2.9×14.3%-5.8%
Daan Gene 002030.SZChina$1.05B-17%+1%-81%8.0×4.8%-32.3%
Duality Biotherapeutics 9606.HKHong Kong$1.06B-58%-5%-181%5.6×n/an/a
China Animal Husbandry Industry 600195.SSChina$921M-16%+1%2%1.3×6.1%+4.4%
Jade Biosciences JBIOUnited States$1.07B-34%n/an/an/an/an/a
Innovita Biological Technology 688253.SSChina$915M-28%-28%11%14.0×39.6%-16.6%
Odyssey Therapeutics ODTXUnited States$912M+12%-33%-5,415%204.9×n/an/a
Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZChina$909M-15%0%22%4.2×9.2%+2.3%
GNI 2160.TJapan$903M-25%+44%-21%6.2×n/an/a
Vor Biopharma VORUnited States$1.10B+15%n/an/an/an/an/a
Peptidream 4587.TJapan$878M-3%+14%-18%6.6×n/an/a
Verastem VSTMUnited States$866M+66%+650%-194%8.2×n/an/a
COMPASS Pathways Plc Sponsored ADR CMPSUnited States$1.15B-25%n/an/an/an/an/a
Kardigan KARDUnited States$1.15Bn/an/an/an/an/an/a
Oxford BioMedica OXB.LUnited Kingdom$841M-15%+16%-18%4.1×n/an/a
Akums Drugs and Pharmaceuticals AKUMS.NSIndia$1.21B+38%+18%10%2.0×15.3%+9.9%
MeiraGTx MGTXUnited States$813M-13%+1,366%44%1.9×n/an/a

Questions

Which companies are SpyGlass Pharma's closest peers?
The cockpit's peer set: Changchun BCHT Biotechnology (688276.SS), Inhibrx Biosciences (INBX), Alto Neuroscience (ANRO), Guangzhou Wondfo Biotech (300482.SZ), Daan Gene (002030.SZ), Duality Biotherapeutics (9606.HK), China Animal Husbandry Industry (600195.SS), Jade Biosciences (JBIO).
How has SpyGlass Pharma stock performed?
Over six months to 18 Nov 2026 the shares returned +35.6% against -15.1% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.